Selected data models

You must log in to select data models for download or further analysis.

9 Search results.
Relevance Rating New first Old first

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Month 4 CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 8 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER, PREGNANCY TEST PROMPT, HIV RNA PROMPT, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Month 6 End of Study CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 7 itemgroups, 3 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, PREGNANCY TEST PROMPT, HIV RNA PROMPT, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Month 5 CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 6 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Unscheduled Visit CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 3 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Month 3 CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 8 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER, PREGNANCY TEST PROMPT, HIV RNA PROMPT, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Month 2 CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 6 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Month 1 CENTRAL LABORATORY BLOOD NCT00079911 - GSK Study Month 1 CENTRAL LABORATORY BLOOD NCT00079911

- 7/28/17 - 1 form, 8 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER, PREGNANCY TEST PROMPT, HIV RNA PROMPT, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Randomisation Visit CENTRAL LABORATORY BLOOD NCT00079911 - GSK Study Randomisation Visit CENTRAL LABORATORY BLOOD NCT00079911

- 7/12/17 - 1 form, 8 itemgroups, 4 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY BLOOD, INVESTIGATIONAL PRODUCT CONTAINER NUMBER, PREGNANCY TEST PROMPT, HIV RNA PROMPT, HIV-ASSOCIATED CONDITIONS, CONCOMITANT MEDICATIONS, ADVERSE EVENTS
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons Screening Visit CENTRAL LABORATORY- BLOOD NCT00079911 - GSK Study Screening Visit CENTRAL LABORATORY- BLOOD NCT00079911

- 7/11/17 - 1 form, 2 itemgroups, 6 items, 1 language
Itemgroups: Study administration, CENTRAL LABORATORY - BLOOD
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial